Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
Recent News & Events
Novo Nordisk's termination of the collaboration removes a partnership backstop and milestone/royalty optionality, a near-term negative offset by advancing KRRO-121 clinical progress and a cash runway into H2 2028.
NEGATIVENov 3, 2026
Partnership Termination
Novo Nordisk Terminates Korro Collaboration for Convenience
Korro received written notice on Nov 3, 2026 that Novo Nordisk elected to terminate the September 2024 research collaboration and license agreement for convenience, effective February 1, 2027. Novo Nordisk did not nominate a second target and no milestones were earned; the loss of future milestone/royalty optionality and validation from a major partner is likely to weigh on near-term sentiment, though no termination penalties apply and prior payments are non-refundable.
Korro reported Q3 2026 results on Nov 5, 2026 with a net loss of $17.5M and cash of $124.8M, funding operations into H2 2028. The update highlighted KRRO-121 first-in-human dosing, FDA rare pediatric disease designation, and best-in-class KRRO-111 preclinical data, providing a balanced mix of pipeline progress against the Novo termination overhang.
Korro announced dosing of the first cohort of healthy volunteers (2 mg/kg) in the global Phase 1/2 ANCHOR trial of KRRO-121 for hyperammonemia in UCDs and HE, with UCD patient dosing expected in H1 2027 and interim data in H2 2027. Continued clinical execution supports the pipeline narrative and could provide modest positive sentiment.
FDA Rare Pediatric Disease Designation for KRRO-121
Korro received FDA rare pediatric disease designation for KRRO-121 in UCDs, which may confer priority review voucher eligibility upon approval and highlights regulatory recognition of the program. This is a modest positive catalyst supporting the KRRO-121 development path.